Tirzepatide vs Semaglutide: What Is Actually Different

It is a reasonable question and it has a genuinely interesting answer. Tirzepatide produces more weight loss in head-to-head trials, while both drugs now have cardiovascular outcome evidence in type 2 diabetes. Where semaglutide still has an evidence advantage is in people with established cardiovascular disease who do not have diabetes. Those distinctions matter, and which one matters most depends entirely on who is asking.

The mechanical difference

Semaglutide is a GLP-1 receptor agonist. It acts at one receptor, for one gut hormone, glucagon-like peptide 1. That hormone slows gastric emptying, increases insulin release in response to a meal, suppresses glucagon, and acts on appetite centres in the brain.

Tirzepatide acts at two. It is an agonist at the GLP-1 receptor and also at the receptor for glucose-dependent insulinotropic polypeptide, GIP. Hence the shorthand you will see, dual agonist or twincretin.

That is the entire structural difference, and it is worth being honest about how well we understand it. The role GIP plays here is not settled. GIP agonism improves metabolic outcomes in these trials, and yet GIP antagonism has also shown metabolic benefit in other models, which is an uncomfortable pair of findings to hold at once. The field does not have a complete explanation. Anyone who tells you precisely why the second receptor helps is ahead of the evidence.

Mounjaro, Ozempic, Zepbound, Wegovy: which is which

The brand names cause more confusion than the pharmacology does, because each molecule is sold under two names depending on what it was approved to treat.

Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for weight management. Same molecule, same dosing, different label and often a very different price.

Semaglutide is sold as Ozempic for type 2 diabetes, as Wegovy for weight management, and as Rybelsus in an oral tablet form for type 2 diabetes.

So Mounjaro versus Ozempic and Zepbound versus Wegovy are the same comparison in different packaging. If you are comparing them, you are comparing tirzepatide with semaglutide.

What the trials show

In the SURMOUNT-1 trial, adults with obesity or overweight without diabetes taking tirzepatide 15 mg for 72 weeks lost around 20.9 percent of body weight on average. In STEP 1, semaglutide 2.4 mg over 68 weeks produced a mean reduction of around 14.9 percent.

Do not read those two numbers side by side and conclude anything. Different trials, different populations, different durations, different eras. Cross-trial comparison is one of the most common ways to be confidently wrong about medicine.

What settles it is a direct comparison, and there is one. SURMOUNT-5 randomised 751 adults with obesity and without diabetes to tirzepatide or semaglutide and followed them for 72 weeks. Tirzepatide produced a mean weight reduction of 20.2 percent against 13.7 percent for semaglutide, and a larger reduction in waist circumference, 18.4 cm against 13.0 cm. That is a real difference and it is the honest answer to the weight loss question.

What each one has proven about your heart

This is the part that gets left out of the comparison, and for some of my patients it is the part that decides the prescription. It also changed in the last few days, so anything you read on this a month ago is already behind.

On 28 August 2026 the FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with type 2 diabetes who are at high risk of those events. The approval rests on SURPASS-CVOT, which enrolled more than 13,000 people across 30 countries and ran for around four and a half years, comparing tirzepatide against dulaglutide. Tirzepatide showed an 8 percent lower rate of those events, a hazard ratio of 0.92. So tirzepatide now carries a cardiovascular indication of its own, and a month ago it did not.

Semaglutide has carried a cardiovascular indication in type 2 diabetes for some years. In a patient with diabetes, both drugs now have one, and the choice turns on other things.

The difference that remains is about which population the evidence comes from, and for most people reading this it is the one that matters. The SELECT trial studied semaglutide 2.4 mg in 17,604 adults aged 45 and over, with a BMI of 27 or higher and established cardiovascular disease, but without diabetes. Against placebo, over a mean follow up of around 40 months, major adverse cardiovascular events occurred in 6.5 percent of the semaglutide group against 8.0 percent on placebo. A hazard ratio of 0.80, which is a 20 percent relative risk reduction, against placebo, in people who did not have diabetes.

Tirzepatide does not have that trial yet. SURMOUNT-MMO asks the equivalent question in obesity without diabetes and is still running.

Semaglutide also has kidney outcome data in type 2 diabetes with chronic kidney disease, from the FLOW trial.

So the honest position as I write this. If you have type 2 diabetes, both drugs now carry cardiovascular indications and the decision rests elsewhere. If you have obesity and established heart disease but not diabetes, semaglutide currently has outcome evidence in your exact situation and tirzepatide does not yet. That gap may close. It has not closed today.

Side effects

Broadly similar, and mostly gastrointestinal on both. Nausea, vomiting, diarrhoea, constipation, and reflux. These are usually worst during dose escalation and settle with time and slower titration.

Both carry the same boxed warning regarding thyroid C-cell tumours observed in rodent studies. Both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. That contraindication is the single most important question I ask before prescribing either, and it is one people frequently do not know the answer to until they call a relative.

Both are once-weekly injections. Both require dose escalation over months rather than starting at target dose.

So which is better

Better at what, and better for whom.

If the only variable is weight reduction, the head-to-head evidence favours tirzepatide. If you have established cardiovascular disease and type 2 diabetes, both now carry cardiovascular indications. If you have established cardiovascular disease without diabetes, semaglutide has the outcome trial in that population and tirzepatide does not yet. If you have obstructive sleep apnoea, tirzepatide has an indication for it. If one is covered by your insurance and the other is not, that is frequently the deciding factor regardless of what either of us would prefer, and I would rather have you consistently on the second-best option than intermittently on the first.

Tolerability decides more of these than the trial data does. A drug you stop after six weeks because you cannot function does not work, whatever the average result says.

And the point I keep returning to with patients: the molecule is the least interesting part of this decision. Neither of these builds muscle, neither teaches you to eat differently, and both hand back most of what they achieved when they stop if nothing else has changed. We wrote about that at length in why a GLP-1 is not a treatment plan, and about the specific problem of losing lean tissue alongside fat in protecting muscle while you are on a GLP-1.

If you are starting either of these and want to know what the underlying metabolic picture looks like first, that conversation usually begins with what insulin resistance actually is.

Sources: SURMOUNT-5, tirzepatide compared with semaglutide, NEJM 2025 · SURMOUNT-1, NEJM 2022 · STEP 1, NEJM 2021 · SELECT, NEJM 2023 · FDA approval of Mounjaro for cardiovascular risk reduction, August 2026 · FDA prescribing information

If any of this sounds like your experience, you can book a virtual consultation with Dr. Sater to review your history and testing in full.